Genmab has approximately 20 active in-house and partnered pre-clinical programs. Our pre-clinical pipeline includes naked antibodies, bispecific antibodies developed using our DuoBody® technology, immune effector function enhanced antibodies developed with our HexaBody® technology and Antibody-Drug Conjugates (ADC). Genmab is committed to innovation and therefore investigates new ways of creating and improving antibody therapeutics. A number of the pre-clinical programs are carried out in cooperation with our collaboration partners.

Back to top